Perspective Therapeutics, Inc. Common Stock

Financials

İşletme faaliyetlerinden elde edilen nakit -2.84 M-7.71 M-36.91 M-18.29 M-82.48 M -92.37 M Yatırım faaliyetlerinden elde edilen nakit -410 K-284 K24.37 M-218.93 M41.23 M -62.76 M Finansman faaliyetlerinden elde edilen nakit 64.68 M56 K785 K289.38 M10.3 M 164.7 M Serbest nakit akışı -2.84 M-7.71 M-36.91 M-18.29 M-95.23 M -107.32 M

Isoray Inc. is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is a registered manufacturer with the FDA and holds multiple 510 clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu. The company went public in 2005. Isoray’s corporate headquarters is located at 350 Hills Street, Suite 106, Richland WA 99354.

CATX

Financials

Perspective Therapeutics, Inc. Common Stock

Haberler

Perspective Therapeutics iki deneme kohortunda ilk hastalara doz verdi

RBC Capital, Perspective Therapeutics hissesi için Outperform görüşünü korudu

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst Call - Slideshow (NYSE:CATX) 2026-05-04

Perspective Therapeutics - Decent Prospect In Radiopharmaceuticals Field (NYSE:CATX)

H.C. Wainwright, Perspective Therapeutics için hedef fiyatı 13 dolara yükseltti

Jones Trading, Perspective Therapeutics hissesi için Al tavsiyesini yineledi

Truist, Perspective Therapeutics hissesi için Al tavsiyesini yineledi

Truist reiterates Buy on Perspective Therapeutics stock

RBC, model güncellemeleri sonrası Perspective Therapeutics hisse hedefini düşürdü

RBC cuts Perspective Therapeutics stock price target on model updates

BTIG, Perspective Therapeutics hissesi için Al tavsiyesini yineledi